Chitharanjan Duvoor
Endocrinology, Diabetes & Metabolism · Jonesboro, ARNPI 1609131234
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 59 manufacturers reported payments, led by Abbott at 32.6% of the total. 2025 is the largest year on record at $27,433, 4.3 times the $6,368 reported in 2019.
Across 1,350 payments — averaging $56.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$25K
- Dexcom, Inc.$24K
- Medtronic$3K
- Bayer$2K
- Amgen$2K
- AstraZeneca$2K
- plus $17K from 53 others
What the payments were for
- Consulting fees$8,85912%
- Speaking & faculty fees$31,90142%
- Travel & lodging$8,54111%
- Food & beverage$25,92034%
- Education$5151%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$23,297
- DEXCOM G7 GSS (161)$22,970
- DEXCOM STELO GLUCOSE BIOSENSOR$5,531
- Kerendia$1,334
- Minimed 670G System$962
- Korlym$618
- MINIMED 780G$422
- Strensiq$326
- iLet Bionic Pancreas$300
- KRYSTEXXA$143
- CeQur Simplicity$125
- CRYSVITA$115
- TWIIST$111
- Ozempic$109
- Senza$100
- iLet Insulin Infusion Kit Inset$100
- iLet Insulin Infusion Kit Contact Detach$100
How this compares
$75,735 in reported general payments places this provider in the 85th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
See all endocrinology, diabetes & metabolism providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 1,348 | $1,857,725 |
| OzempicSemaglutide | 985 | $1,331,449 |
| JardianceEmpagliflozin | 1,098 | $1,031,535 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 336 | $330,155 |
| FarxigaDapagliflozin Propanediol | 401 | $318,095 |
| TrulicityDulaglutide | 228 | $293,414 |
| Tresiba Flextouch U-200Insulin Degludec | 250 | $269,974 |
| Humalog Kwikpen U-200Insulin Lispro | 103 | $263,113 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 130 | $257,204 |
| TymlosAbaloparatide | 70 | $245,411 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 187 | $212,971 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 125 | $145,652 |
| Tresiba Flextouch U-100Insulin Degludec | 199 | $136,871 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 131 | $111,184 |
| Novolog FlexpenInsulin Aspart | 358 | $105,682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $1,715 | $2,185,7931,647 claims |
| Novo NordiskOzempic, Novolog, Fiasp, Rybelsus | $1,885 | $1,403,9971,111 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Trijardy Xr | $755 | $1,131,1121,209 claims |
| AstraZenecaFarxiga | $2,084 | $318,095401 claims |
| Radius Health, Inc.Tymlos | $922 | $245,41170 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,061 | $212,971187 claims |
| BayerKerendia | $2,276 | $35,58929 claims |
| MerckJanuvia | $224 | $28,42229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
Other endocrinology, diabetes & metabolism in Jonesboro
- Kevin GanongJonesboro$131K
- Richard GriffithsLittle Rock$925K
- Catherine KilpatrickFayetteville$690K
- Adam MaassSpringdale$502K
- James ThrasherLittle Rock$349K
- Cory GambleFort Smith$112K
- Richard RappLittle Rock$47K
- Shunzhong BaoLittle Rock$40K
- Jason DailyFayetteville$35K
- Daryl BurrowsHot Springs$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.